These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27177586)

  • 41. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study.
    Hatz C; Soto J; Nothdurft HD; Zoller T; Weitzel T; Loutan L; Bricaire F; Gay F; Burchard GD; Andriano K; Lefèvre G; De Palacios PI; Genton B
    Am J Trop Med Hyg; 2008 Feb; 78(2):241-7. PubMed ID: 18256423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria.
    Lohy Das J; Rulisa S; de Vries PJ; Mens PF; Kaligirwa N; Agaba S; Tarning J; Karlsson MO; Dorlo TPC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.
    Vos K; Sciuto CL; Piedade R; Ashton M; Björkman A; Ngasala B; Mårtensson A; Gil JP
    Pharmacogenomics; 2017 Jul; 18(10):981-985. PubMed ID: 28639487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo efficacy of artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo.
    de Wit M; Funk AL; Moussally K; Nkuba DA; Siddiqui R; Bil K; Piriou E; Bart A; Bahizi Bizoza P; Bousema T
    Malar J; 2016 Sep; 15(1):455. PubMed ID: 27599612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of lumefantrine-artemether (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults.
    Mulenga M; VangGeertruyden JP; Mwananyanda L; Chalwe V; Moerman F; Chilengi R; Van Overmeir C; Dujardin JC; D'Alessandro U
    Malar J; 2006 Aug; 5():73. PubMed ID: 16923176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Understanding the pharmacokinetics of Coartem.
    Djimdé A; Lefèvre G
    Malar J; 2009 Oct; 8 Suppl 1(Suppl 1):S4. PubMed ID: 19818171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.
    White NJ; van Vugt M; Ezzet F
    Clin Pharmacokinet; 1999 Aug; 37(2):105-25. PubMed ID: 10496300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Artemether-lumefantrine: an option for malaria.
    Stover KR; King ST; Robinson J
    Ann Pharmacother; 2012 Apr; 46(4):567-77. PubMed ID: 22496476
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treating malaria in pregnant women: a pressing problem.
    Gutman J; Kachur SP
    Lancet Infect Dis; 2010 Nov; 10(11):739-40. PubMed ID: 21029982
    [No Abstract]   [Full Text] [Related]  

  • 50. Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study.
    Ebstie YA; Zeynudin A; Belachew T; Desalegn Z; Suleman S
    Malar J; 2015 Jun; 14():236. PubMed ID: 26045199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects.
    Abdulla S; Amuri B; Kabanywanyi AM; Ubben D; Reynolds C; Pascoe S; Fitoussi S; Yeh CM; Nuortti M; Séchaud R; Kaiser G; Lefèvre G
    Malar J; 2010 Sep; 9():253. PubMed ID: 20815879
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial.
    Piola P; Fogg C; Bajunirwe F; Biraro S; Grandesso F; Ruzagira E; Babigumira J; Kigozi I; Kiguli J; Kyomuhendo J; Ferradini L; Taylor W; Checchi F; Guthmann JP
    Lancet; 2005 Apr 23-29; 365(9469):1467-73. PubMed ID: 15850630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria.
    Mwebaza N; Jerling M; Gustafsson LL; Silva AV; Pohanka A; Obua C; Waako P; Beck O; Homann MV; Färnert A; Hellgren U
    Basic Clin Pharmacol Toxicol; 2017 May; 120(5):457-465. PubMed ID: 27883269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso.
    Valea I; Tinto H; Traore-Coulibaly M; Toe LC; Lindegardh N; Tarning J; Van Geertruyden JP; D'Alessandro U; Davies GR; Ward SA
    J Antimicrob Chemother; 2014 Sep; 69(9):2499-507. PubMed ID: 24891429
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rational dispensing and use of artemether-lumefantrine during pregnancy in Dar es Salaam, Tanzania.
    Kamuhabwa AR; Mnyusiwalla F
    Tanzan J Health Res; 2011 Apr; 13(2):106-13. PubMed ID: 25566607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Benin.
    Ogouyèmi-Hounto A; Azandossessi C; Lawani S; Damien G; de Tove YS; Remoue F; Kinde Gazard D
    Malar J; 2016 Jan; 15():37. PubMed ID: 26801767
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of six-dose regimen of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria, three years after its introduction into Ethiopia.
    Kefyalew T; Animut A; Tamene T; Jima D; Hailemariam A; Legesse M
    Parasite; 2009 Jun; 16(2):129-34. PubMed ID: 19585891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of the therapeutic efficacy of a paediatric formulation of artemether-lumefantrine (Coartesiane) for the treatment of uncomplicated Plasmodium falciparum in children in Zambia.
    Chanda P; Hawela M; Kango M; Sipilanyambe N
    Malar J; 2006 Aug; 5():75. PubMed ID: 16938133
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda.
    Kaye DK; Nshemerirwe R; Mutyaba TS; Ndeezi G
    J Infect Dev Ctries; 2008 Apr; 2(2):135-9. PubMed ID: 19738339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.